Takeda Pharmaceutical has signed a major $1.7 billion deal with biotech firm Iambic, marking a fresh push to use AI drug discovery to speed up small-molecule research in cancer and gastrointestinal diseases.
Sun Pharmaceutical will invest Rs 500 crore to set up a drug manufacturing plant in Assam. The project will be rolled out in two phases and is expected to generate direct employment for over 500 people.
Lupin has launched Topiramate Extended-Release Capsules in the U.S. after receiving FDA approval for its ANDA, expanding access to treatments for epilepsy and migraine prevention.
NATCO Pharma gets USFDA tentative approval for its generic Erdafitinib, a treatment for advanced urothelial carcinoma, offering a more affordable option for cancer patients.
Indoco Remedies has received USFDA approval for its ANDA for Lacosamide Oral Solution, a generic version of Vimpat. The approval strengthens the company’s growing footprint in the U.S. generics market.
Union Budget 2026 boosts India’s biopharma and healthcare sectors with Rs 10,000 crore for Biopharma SHAKTI, creating new opportunities for innovation, manufacturing, and patient care.
Pharma stocks are soaring after the Budget 2026 announcement of a Rs 10,000 crore biopharma push. This move under the Biopharma Shakti initiative is set to strengthen India's role in global healthcare, driving investment and innovation.
Wockhardt’s Foviscu (WCK 4282) hits its Phase 3 endpoint, showing clinical cure rates comparable to meropenem for complicated UTIs, including ESBL infections, offering a vital alternative for antibiotic-resistant cases.
Naprod Life Sciences has secured an ANVISA GMP renewal for its Tarapur manufacturing facility, reinforcing its compliance with Brazil’s regulatory standards and supporting continued exports of oncology and specialty pharmaceutical products.
Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of Nivolumab in India. This launch provides cancer patients with an affordable, reliable alternative to expensive treatments, ensuring improved access to life-saving therapies.
, CDSCO.jpg)